Twu CW, Wang WY, Tsou HH, et al. - In this retrospective study, researchers reported the long-term result of stage III nasopharyngeal carcinoma (NPC) patients treated with combined chemoradiotherapy and examined the prognostic effect of different treatment modality and pretreatment plasma EBV DNA load as a reference for future therapy improvement. Among 356 stage III NPC patients, the initial definitive treatment consisted of concurrent chemoradiotherapy (CCRT) or induction chemotherapy plus radiotherapy (IndCT-RT). The 5-year rates of overall survival (OS), progression-free survival (PFS), distant metastasis failure-free survival (DMFFS), and locoregional failure-free survival (LRFFS), respectively, were 88.6%, 83.0%, 90.5%, and 90.5%. The long-term outcomes of treatment for patients with stage III NPC are fairly good. IndCT-RT will achieve the same result for treatment as CCRT. Risk grouping by viral load pretreatment identified a subgroup of patients related to significantly higher relapse rates and worse survivals. Such high-risk patients must strengthen the intensity of the treatment in future trials.